Finance Compliance Manager - Technology and Data
About the job
- A bachelor's degree in Finance, Economics, or a related field is required.
- At least 8 years of previous experience in Finance roles is required, preferably including significant system transformation projects.
- Solid knowledge of financial and information technology internal controls is required.
- Solid knowledge of SOX 404, United States Generally Accepted Accounting Principles, and International Financial Reporting Standards is required.
- Solid knowledge of supply chain environments is required.
- Ability to proactively identify and mitigate process risks.
- Understanding of continuous process improvement techniques.
- Ability to anticipate needs, assess and manage business risk, escalate issues that may impact the process globally, and manage through crisis and ambiguity.
- Experience working in a sophisticated, multi-enterprise resource planning or system environment.
- People leadership skills and ability to collaborate in a highly matrixed environment.
- Support Finance Transformation Compliance governance for SAP-driven transformation initiatives, focusing on technology, system configuration, and data-related risks.
- Translate enterprise internal control over financial reporting, Sarbanes-Oxley, and information technology general controls frameworks into transformation-specific compliance requirements for SAP S/4HANA and related technologies.
- Act as the primary compliance point of contact for SAP and technology-related compliance topics within assigned transformation programs and value streams.
- Guide and lead technology-focused risk assessments, including SAP application risks, information technology general controls, and data-integrity considerations.
- Ensure consistent design and application of information technology general controls, including access management, organizational change, computer operations, and configuration controls.
- Provide compliance guidance on SAP configurations, workflows, and system-enabled controls to align with internal control and Sarbanes-Oxley requirements.
- Define and apply compliance expectations for system interfaces, including source-to-target controls, error handling, reconciliation, and supervisory mechanisms.
- Review and challenge program-level compliance artifacts related to SAP and information technology controls for completeness, consistency, and alignment with approved methodologies.
- Supervise technology- and data-related compliance risks across transformation initiatives, identify emerging issues, and escalate material risks to the Senior Manager.
- Coordinate across programs to manage shared SAP platforms, common interfaces, and cross-system dependencies from a compliance perspective.
- Contribute to the development and refinement of compliance guidance and methodologies related to information technology general controls, SAP risks, and data integrity.
- Ensure documentation and traceability of compliance decisions, assessments, and governance outcomes within assigned transformation initiatives.
- Promote a risk-based, pragmatic approach to technology and data compliance while maintaining control effectiveness.
- Serve as a domain expert for auditors by explaining design principles, risk assessments, and information technology general controls risks and control matrices.
- Experience in significant system transformation projects.
- Experience with SAP S/4HANA.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
- TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
- CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.
What critics are saying
- Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
- Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
- AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.
What makes Johnson & Johnson unique
- J&J has 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
- CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.